University Hospital Schleswig-Holstein

Kiel DE-24105

4 studies enrolling now · 13 studies all time

What they study most

Advanced Melanoma, Atrial Functional Mitral Regurgitation, Breast Neoplasms, Colitis, Ulcerative, Crohn's Disease, HER2+ Metastatic Breast Cancer (MBC), HER2-Positive Primary Breast Cancer, Inflammatory Bowel Diseases, MF, Mitral Insufficiency, Myelofibrosis, Oral Mucositis

Studies at this site

• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Recruiting now
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — Recruiting now
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR) — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Running, not enrolling
• A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC — Running, not enrolling
• Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis — Completed
• The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis — Stopped early
• Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) — Status unconfirmed
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting — Completed
• Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day — Stopped early
• Ultrasound Elastography of Breast Lesions — Completed